GeneAssess is working to validate FRY, a cancer molecular signature gene discovered by their scientists, which has shown potential as a more accurate diagnostic biomarker for cancer staging. The gene has been found in the breast cancer model and has also demonstrated promising results in reducing the growth of aggressive human breast cancer cells in animal models. GeneAssess plans to validate FRY as a predictive biomarker for breast and other cancers, detect genetic mutations in at-risk populations, and explore target validation for FRY. The company holds an exclusive license to the intellectual property developed by Dr. Zarbl.